28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
CBS Aβ+ group showed a reduced Aβ42/40 ratio, with elevated phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentrations, while CBS Aβ- group only showed elevated NfL concentration compared to CU. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
There has been a rapid growth in research on peripheral fluid biomarkers for Alzheimer's disease (AD) and AD-related dementias, because they are non-invasive, relatively inexpensive and easily accessible. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Asthma participants had widespread and large-magnitude differences in several dMRI metrics, which were indicative of neuroinflammation and neurodegeneration, and which were robustly associated with GFAP and, to a lesser extent, NfL. 5 key findings →
Participants: 111 Evidence: low
Full summary, score breakdown and related studies → Original source
Abnormal levels of plasma glial fibrillary acidic protein (GFAP) were found at the prodromal stage of MCI-LB in association with increased amyloid PET. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The common marmoset (Callithrix jacchus), a small South American monkey, is an important nonhuman primate model in the study of aging and age-related neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, and related dementias. 1 key finding →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source
Blood-based biomarkers of neurodegeneration demonstrate great promise for the diagnosis and prognosis of Alzheimer's disease. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Discrimination of disease-related interactions of the core subsystem and FPN was found in AD-spectrum patients, which was the neural circuit fundamental to plasma NFL disrupting cognitive integrity. 3 key findings →
Participants: 112 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma neurofilament light chain (NfL)'s link to dementia may be mediated through white matter integrity (WMI). 2 key findings →
Participants: 163 Evidence: low
Full summary, score breakdown and related studies → Original source
NFL discriminated patients from controls with an area under the curve of 0.914 (95% CI, 0.843-0.984; p < 0.001) (cut-off: 76.46 pg/mL; 94% sensitivity, 76.9% specificity). 5 key findings →
Participants: 80 Evidence: low
Full summary, score breakdown and related studies → Original source
Testing an Alzheimer's disease continuum cohort, the area under the curve (AUC), sensitivity, specificity, and accuracy for the p-tau217/Aβ42 ratio reached 0.961, 93%, 92%, and 93%, respectively. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among the hip fracture patients, 88.6% of the cognitively normal (Clinical Dementia Rating-CDR 0; n = 70) and 98.8% with mild cognitive impairment (CDR 0.5; n = 81) fell in the abnormal biomarker categories by the A/T/N classification. 3 key findings →
Participants: 70 Evidence: low
Full summary, score breakdown and related studies → Original source
Studying the correlation between cerebrospinal fluid (CSF) metabolites and the Alzheimer's Disease (AD) biomarkers may offer a window to the alterations of the brain metabolome and unveil potential biological mechanisms underlying AD. 4 key findings →
Participants: 338 Evidence: low
Full summary, score breakdown and related studies → Original source
Β-site amyloid precursor protein (APP) cleaving enzyme (BACE1) is a crucial protease in the production of amyloid-β (Aβ) in Alzheimer's disease (AD) patients. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma amyloid-β (Aβ) was associated with brain Aβ deposition and Alzheimer's disease (AD) development. 4 key findings →
Participants: 449 Evidence: low
Full summary, score breakdown and related studies → Original source
Amnestic mild cognitive impairment (aMCI) is considered a prodromal stage of Alzheimer's disease (AD). 2 key findings →
Participants: 191 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The definition of Alzheimer's disease (AD) now considers the presence of the markers of amyloid (A), tau deposition (T), and neurodegeneration (N) essential for diagnosis. 2 key findings →
Participants: 172 Evidence: low
Full summary, score breakdown and related studies → Original source
The degree of PVS significantly increased with age in both, BG and CS regions independently of cardiovascular risk factors. 4 key findings →
Participants: 322 Evidence: low
Full summary, score breakdown and related studies → Original source
The preliminary diagnosis of AD was made in 3 patients (5%). 5 key findings →
Participants: 64 Evidence: low
Full summary, score breakdown and related studies → Original source
No significant disparities in plasma ubiquitin levels for various levels of cognitive functioning were identified. 5 key findings →
Participants: 230 Evidence: low
Full summary, score breakdown and related studies → Original source
Twenty-nine percent of the cohort had Montreal Cognitive Assessment (MoCA) scores indicative of cognitive impairment or dementia after adjusting for age, sex, and education based on National Alzheimer's Coordinating Center normative data. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
There were significant differences in plasma p‐tau181 values between Controls and those with AD at all ages up to 85 years. 5 key findings →
Participants: 1,558 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma p‐tau181 differentiated pathology‐confirmed AD from NC with negative amyloid PET scans with an AUC of 0.93. 5 key findings →
Participants: 91 Evidence: moderate
Full summary, score breakdown and related studies → Original source
BBBO was achieved in 5 out of 6 subjects with an average volume of 983 ± 626 mm 3 following FUS at the right frontal lobe both in white and gray matter regions. 5 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
It is unknown how neuroinflammation may feature in the etiology of Alzheimer's disease (AD). 1 key finding →
Participants: 1,291 Evidence: low
Full summary, score breakdown and related studies → Original source
Linear models showed that plasma GFAP was significantly higher in αSyn+AD compared to αSyn (β = 0.31, 95% CI = 0.065-0.56, and P = 0.015), after covarying for age at plasma, plasma-to-death interval, and sex; plasma p-tau 181 was not (P = 0.37). 4 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →